Henguru
2021-09-13
Nice
Ocugen shares surged more than 13% in Monday morning trading<blockquote>Ocugen股价周一早盘飙升逾13%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":886950607,"tweetId":"886950607","gmtCreate":1631545257209,"gmtModify":1631889365715,"author":{"id":3574984776649901,"idStr":"3574984776649901","authorId":3574984776649901,"authorIdStr":"3574984776649901","name":"Henguru","avatar":"https://static.tigerbbs.com/0c8ff792ba806e41257f86794576430f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":37,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Nice</p></body></html>","htmlText":"<html><head></head><body><p>Nice</p></body></html>","text":"Nice","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/886950607","repostId":1126978010,"repostType":4,"repost":{"id":"1126978010","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631544701,"share":"https://www.laohu8.com/m/news/1126978010?lang=zh_CN&edition=full","pubTime":"2021-09-13 22:51","market":"us","language":"en","title":"Ocugen shares surged more than 13% in Monday morning trading<blockquote>Ocugen股价周一早盘飙升逾13%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1126978010","media":"Tiger Newspress","summary":"Ocugen shares surged more than 13% in Monday morning trading.\n\nVarious companies have been engaged i","content":"<p>Ocugen shares surged more than 13% in Monday morning trading.</p><p><blockquote>Ocugen股价在周一早盘交易中飙升超过13%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/8fcba6c91ee88af0dd90608a79065282\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Various companies have been engaged in producing COVID-19 vaccines since the onset of the pandemic.</p><p><blockquote>自疫情爆发以来，多家公司一直在生产新冠肺炎疫苗。</blockquote></p><p> Clinical-stage biotech firm Ocugen (<b>OCGN</b>) joined the race in December 2020, announcing its partnership with India-based Bharat Biotech. Ocugen collaborated with the Indian biotech company to jointly develop Covaxin.</p><p><blockquote>临床阶段生物技术公司Ocugen（<b>OCGN</b>）于2020年12月加入竞争，宣布与印度Bharat Biotech合作。Ocugen与印度生物技术公司合作，共同开发科瓦克辛。</blockquote></p><p> The announcement helped its stock to propel from under 30 cents a share to a stunning, eventual high of $18.77 a share in February. However, prices plummeted to nearly $9 per share in the next month.</p><p><blockquote>这一公告帮助其股价从每股30美分以下上涨至2月份每股18.77美元的惊人高点。然而，在接下来的一个月里，价格暴跌至每股近9美元。</blockquote></p><p> As rival companies came forward with their vaccines while Ocugen lagged behind, the stock started to bleed.</p><p><blockquote>随着竞争对手公司推出疫苗，而Ocugen却落后了，该股开始下跌。</blockquote></p><p> However, OCGN stock is once again witnessing an upward move. Here’s a detailed analysis to find out what’s really happening with the stock. I’m neutral on Ocugen.</p><p><blockquote>然而，OCGN股票再次出现上涨。这里有一个详细的分析，以了解股票的真实情况。我对Ocugen持中立态度。</blockquote></p><p> <b>Delta Variant Concerns Pushing OCGN Stock up</b></p><p><blockquote><b>德尔塔变异毒株担忧推高OCGN股价</b></blockquote></p><p> Newly discovered variants of COVID-19 have been a major cause of concern lately. These variants are more infectious, and resistant, to the already existing COVID-19 vaccines. The Delta variant is one such dangerous strain that has caught the attention of people worldwide.</p><p><blockquote>新发现的新冠肺炎变种是最近令人担忧的主要原因。这些变种对现有的新冠肺炎疫苗更具传染性和耐药性。德尔塔变异毒株病毒就是这样一种危险的菌株，已经引起了全世界人们的注意。</blockquote></p><p> This new variant has piqued global interest in Ocugen, and its Covaxin. Notably, Covaxin is yet to receive approval from FDA. However, the once-forgotten OCGN stock is again back in the discussion, with stock prices moving up by a decent 8.5% in August.</p><p><blockquote>这种新变种激起了全球对Ocugen及其科瓦克辛的兴趣。值得注意的是，科瓦克辛尚未获得FDA的批准。然而，曾经被遗忘的OCGN股票再次回到讨论中，8月份股价上涨了8.5%。</blockquote></p><p> According to many analysts, value investors aren’t interested in this stock. Rather, it is mainly retail investors who are eyeing Ocugen for some quick profit.</p><p><blockquote>许多分析师表示，价值投资者对这只股票不感兴趣。相反，主要是散户投资者关注Ocugen以获取快速利润。</blockquote></p><p> <b>Short-term Catalyst behind the Sudden Spike</b></p><p><blockquote><b>突然飙升背后的短期催化剂</b></blockquote></p><p> Ocugen has been jointly developing Covaxin with Bharat Biotech for use in the North American market. Share prices suffered a decline when Ocugen was denied emergency-use authorization from the FDA, which recommended that the company apply for a biologics-license application instead.</p><p><blockquote>Ocugen一直在与Bharat Biotech联合开发科瓦克辛，用于北美市场。当Ocugen被FDA拒绝紧急使用授权时，股价下跌，FDA建议该公司申请生物制剂许可证申请。</blockquote></p><p> Health Canada is reviewing Covaxin currently. It has not yet been granted approval. However, the news of review was enough to push Ocugen stock higher.</p><p><blockquote>加拿大卫生部目前正在审查科瓦克辛。它尚未获得批准。然而，审查的消息足以推高Ocugen股价。</blockquote></p><p> Moreover, the company intends to submit an Investigational New Drug application for one of its gene therapy candidates. OCU400 is designed to target retinal diseases. Ocugen has already started to assess options to begin trials in Europe in 2022.</p><p><blockquote>此外，该公司打算为其基因治疗候选药物之一提交研究性新药申请。OCU400旨在针对视网膜疾病。Ocugen已经开始评估2022年在欧洲开始试验的选择。</blockquote></p><p> <b>Ocugen Needs to Progress</b></p><p><blockquote><b>Ocugen需要进步</b></blockquote></p><p> The biotech company released a much-awaited business update on August 6. Ocugen failed to generate revenue during the second quarter. Unlike many of its rivals, it doesn’t have any commercialized products at the moment.</p><p><blockquote>这家生物技术公司于8月6日发布了期待已久的业务更新。Ocugen第二季度未能产生收入。与许多竞争对手不同，它目前没有任何商业化产品。</blockquote></p><p> On top of that, it posted a net loss of $26 million during Q2. Expenses related to research and development stood at $18.9 million in the current quarter, as opposed to $1.6 million last year. In addition, administrative expenses increased by 279.8% year-over-year, to $6.8 million.</p><p><blockquote>除此之外，该公司第二季度净亏损2600万美元。本季度与研发相关的费用为1890万美元，而去年为160万美元。此外，管理费用同比增长279.8%，达到680万美元。</blockquote></p><p> As of June 30, cash and cash equivalents stood at $115.6 million.</p><p><blockquote>截至6月30日，现金及现金等价物为1.156亿美元。</blockquote></p><p> <b>Wall Street’s Take</b></p><p><blockquote><b>华尔街的看法</b></blockquote></p><p> As per TipRanks’ analyst rating consensus, Ocugen stock is a Moderate Buy. Out of four analysts, there are two Buy recommendations, and two Hold recommendations.</p><p><blockquote>根据TipRanks的分析师评级共识，Ocugen股票属于适度买入。四位分析师中，有两位建议买入，两位建议持有。</blockquote></p><p> The average OCGN price target is $8.88. The analyst price targets range from a high of $15 per share, to a low of $4.50 per share.</p><p><blockquote>OCGN平均目标价为8.88美元。分析师的目标价范围从每股15美元的高点到每股4.50美元的低点。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/9c696ea686fdeaa8d6550e1282efebf7\" tg-width=\"1099\" tg-height=\"374\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>Bottom Line</b></p><p><blockquote><b>底线</b></blockquote></p><p> Ocugen stock could very well profit from the mounting global concerns about the Delta variant.</p><p><blockquote>Ocugen股票很可能从全球对德尔塔变异毒株日益增长的担忧中获利。</blockquote></p><p> There might even be a stock rally. However, the company is badly in need of positive regulatory updates right now.</p><p><blockquote>股票甚至可能会上涨。然而，该公司目前迫切需要积极的监管更新。</blockquote></p><p> It’s an interesting play, but not without risk.</p><p><blockquote>这是一出有趣的戏，但并非没有风险。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen shares surged more than 13% in Monday morning trading<blockquote>Ocugen股价周一早盘飙升逾13%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen shares surged more than 13% in Monday morning trading<blockquote>Ocugen股价周一早盘飙升逾13%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-09-13 22:51</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Ocugen shares surged more than 13% in Monday morning trading.</p><p><blockquote>Ocugen股价在周一早盘交易中飙升超过13%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/8fcba6c91ee88af0dd90608a79065282\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Various companies have been engaged in producing COVID-19 vaccines since the onset of the pandemic.</p><p><blockquote>自疫情爆发以来，多家公司一直在生产新冠肺炎疫苗。</blockquote></p><p> Clinical-stage biotech firm Ocugen (<b>OCGN</b>) joined the race in December 2020, announcing its partnership with India-based Bharat Biotech. Ocugen collaborated with the Indian biotech company to jointly develop Covaxin.</p><p><blockquote>临床阶段生物技术公司Ocugen（<b>OCGN</b>）于2020年12月加入竞争，宣布与印度Bharat Biotech合作。Ocugen与印度生物技术公司合作，共同开发科瓦克辛。</blockquote></p><p> The announcement helped its stock to propel from under 30 cents a share to a stunning, eventual high of $18.77 a share in February. However, prices plummeted to nearly $9 per share in the next month.</p><p><blockquote>这一公告帮助其股价从每股30美分以下上涨至2月份每股18.77美元的惊人高点。然而，在接下来的一个月里，价格暴跌至每股近9美元。</blockquote></p><p> As rival companies came forward with their vaccines while Ocugen lagged behind, the stock started to bleed.</p><p><blockquote>随着竞争对手公司推出疫苗，而Ocugen却落后了，该股开始下跌。</blockquote></p><p> However, OCGN stock is once again witnessing an upward move. Here’s a detailed analysis to find out what’s really happening with the stock. I’m neutral on Ocugen.</p><p><blockquote>然而，OCGN股票再次出现上涨。这里有一个详细的分析，以了解股票的真实情况。我对Ocugen持中立态度。</blockquote></p><p> <b>Delta Variant Concerns Pushing OCGN Stock up</b></p><p><blockquote><b>德尔塔变异毒株担忧推高OCGN股价</b></blockquote></p><p> Newly discovered variants of COVID-19 have been a major cause of concern lately. These variants are more infectious, and resistant, to the already existing COVID-19 vaccines. The Delta variant is one such dangerous strain that has caught the attention of people worldwide.</p><p><blockquote>新发现的新冠肺炎变种是最近令人担忧的主要原因。这些变种对现有的新冠肺炎疫苗更具传染性和耐药性。德尔塔变异毒株病毒就是这样一种危险的菌株，已经引起了全世界人们的注意。</blockquote></p><p> This new variant has piqued global interest in Ocugen, and its Covaxin. Notably, Covaxin is yet to receive approval from FDA. However, the once-forgotten OCGN stock is again back in the discussion, with stock prices moving up by a decent 8.5% in August.</p><p><blockquote>这种新变种激起了全球对Ocugen及其科瓦克辛的兴趣。值得注意的是，科瓦克辛尚未获得FDA的批准。然而，曾经被遗忘的OCGN股票再次回到讨论中，8月份股价上涨了8.5%。</blockquote></p><p> According to many analysts, value investors aren’t interested in this stock. Rather, it is mainly retail investors who are eyeing Ocugen for some quick profit.</p><p><blockquote>许多分析师表示，价值投资者对这只股票不感兴趣。相反，主要是散户投资者关注Ocugen以获取快速利润。</blockquote></p><p> <b>Short-term Catalyst behind the Sudden Spike</b></p><p><blockquote><b>突然飙升背后的短期催化剂</b></blockquote></p><p> Ocugen has been jointly developing Covaxin with Bharat Biotech for use in the North American market. Share prices suffered a decline when Ocugen was denied emergency-use authorization from the FDA, which recommended that the company apply for a biologics-license application instead.</p><p><blockquote>Ocugen一直在与Bharat Biotech联合开发科瓦克辛，用于北美市场。当Ocugen被FDA拒绝紧急使用授权时，股价下跌，FDA建议该公司申请生物制剂许可证申请。</blockquote></p><p> Health Canada is reviewing Covaxin currently. It has not yet been granted approval. However, the news of review was enough to push Ocugen stock higher.</p><p><blockquote>加拿大卫生部目前正在审查科瓦克辛。它尚未获得批准。然而，审查的消息足以推高Ocugen股价。</blockquote></p><p> Moreover, the company intends to submit an Investigational New Drug application for one of its gene therapy candidates. OCU400 is designed to target retinal diseases. Ocugen has already started to assess options to begin trials in Europe in 2022.</p><p><blockquote>此外，该公司打算为其基因治疗候选药物之一提交研究性新药申请。OCU400旨在针对视网膜疾病。Ocugen已经开始评估2022年在欧洲开始试验的选择。</blockquote></p><p> <b>Ocugen Needs to Progress</b></p><p><blockquote><b>Ocugen需要进步</b></blockquote></p><p> The biotech company released a much-awaited business update on August 6. Ocugen failed to generate revenue during the second quarter. Unlike many of its rivals, it doesn’t have any commercialized products at the moment.</p><p><blockquote>这家生物技术公司于8月6日发布了期待已久的业务更新。Ocugen第二季度未能产生收入。与许多竞争对手不同，它目前没有任何商业化产品。</blockquote></p><p> On top of that, it posted a net loss of $26 million during Q2. Expenses related to research and development stood at $18.9 million in the current quarter, as opposed to $1.6 million last year. In addition, administrative expenses increased by 279.8% year-over-year, to $6.8 million.</p><p><blockquote>除此之外，该公司第二季度净亏损2600万美元。本季度与研发相关的费用为1890万美元，而去年为160万美元。此外，管理费用同比增长279.8%，达到680万美元。</blockquote></p><p> As of June 30, cash and cash equivalents stood at $115.6 million.</p><p><blockquote>截至6月30日，现金及现金等价物为1.156亿美元。</blockquote></p><p> <b>Wall Street’s Take</b></p><p><blockquote><b>华尔街的看法</b></blockquote></p><p> As per TipRanks’ analyst rating consensus, Ocugen stock is a Moderate Buy. Out of four analysts, there are two Buy recommendations, and two Hold recommendations.</p><p><blockquote>根据TipRanks的分析师评级共识，Ocugen股票属于适度买入。四位分析师中，有两位建议买入，两位建议持有。</blockquote></p><p> The average OCGN price target is $8.88. The analyst price targets range from a high of $15 per share, to a low of $4.50 per share.</p><p><blockquote>OCGN平均目标价为8.88美元。分析师的目标价范围从每股15美元的高点到每股4.50美元的低点。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/9c696ea686fdeaa8d6550e1282efebf7\" tg-width=\"1099\" tg-height=\"374\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>Bottom Line</b></p><p><blockquote><b>底线</b></blockquote></p><p> Ocugen stock could very well profit from the mounting global concerns about the Delta variant.</p><p><blockquote>Ocugen股票很可能从全球对德尔塔变异毒株日益增长的担忧中获利。</blockquote></p><p> There might even be a stock rally. However, the company is badly in need of positive regulatory updates right now.</p><p><blockquote>股票甚至可能会上涨。然而，该公司目前迫切需要积极的监管更新。</blockquote></p><p> It’s an interesting play, but not without risk.</p><p><blockquote>这是一出有趣的戏，但并非没有风险。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126978010","content_text":"Ocugen shares surged more than 13% in Monday morning trading.\n\nVarious companies have been engaged in producing COVID-19 vaccines since the onset of the pandemic.\nClinical-stage biotech firm Ocugen (OCGN) joined the race in December 2020, announcing its partnership with India-based Bharat Biotech. Ocugen collaborated with the Indian biotech company to jointly develop Covaxin.\nThe announcement helped its stock to propel from under 30 cents a share to a stunning, eventual high of $18.77 a share in February. However, prices plummeted to nearly $9 per share in the next month.\nAs rival companies came forward with their vaccines while Ocugen lagged behind, the stock started to bleed.\nHowever, OCGN stock is once again witnessing an upward move. Here’s a detailed analysis to find out what’s really happening with the stock. I’m neutral on Ocugen.\nDelta Variant Concerns Pushing OCGN Stock up\nNewly discovered variants of COVID-19 have been a major cause of concern lately. These variants are more infectious, and resistant, to the already existing COVID-19 vaccines. The Delta variant is one such dangerous strain that has caught the attention of people worldwide.\nThis new variant has piqued global interest in Ocugen, and its Covaxin. Notably, Covaxin is yet to receive approval from FDA. However, the once-forgotten OCGN stock is again back in the discussion, with stock prices moving up by a decent 8.5% in August.\nAccording to many analysts, value investors aren’t interested in this stock. Rather, it is mainly retail investors who are eyeing Ocugen for some quick profit.\nShort-term Catalyst behind the Sudden Spike\nOcugen has been jointly developing Covaxin with Bharat Biotech for use in the North American market. Share prices suffered a decline when Ocugen was denied emergency-use authorization from the FDA, which recommended that the company apply for a biologics-license application instead.\nHealth Canada is reviewing Covaxin currently. It has not yet been granted approval. However, the news of review was enough to push Ocugen stock higher.\nMoreover, the company intends to submit an Investigational New Drug application for one of its gene therapy candidates. OCU400 is designed to target retinal diseases. Ocugen has already started to assess options to begin trials in Europe in 2022.\nOcugen Needs to Progress\nThe biotech company released a much-awaited business update on August 6. Ocugen failed to generate revenue during the second quarter. Unlike many of its rivals, it doesn’t have any commercialized products at the moment.\nOn top of that, it posted a net loss of $26 million during Q2. Expenses related to research and development stood at $18.9 million in the current quarter, as opposed to $1.6 million last year. In addition, administrative expenses increased by 279.8% year-over-year, to $6.8 million.\nAs of June 30, cash and cash equivalents stood at $115.6 million.\nWall Street’s Take\nAs per TipRanks’ analyst rating consensus, Ocugen stock is a Moderate Buy. Out of four analysts, there are two Buy recommendations, and two Hold recommendations.\nThe average OCGN price target is $8.88. The analyst price targets range from a high of $15 per share, to a low of $4.50 per share.\n\nBottom Line\nOcugen stock could very well profit from the mounting global concerns about the Delta variant.\nThere might even be a stock rally. However, the company is badly in need of positive regulatory updates right now.\nIt’s an interesting play, but not without risk.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":195,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/886950607"}
精彩评论